Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
线粒体抑制剂 ME-344 或安慰剂联合贝伐单抗治疗早期 HER2 阴性乳腺癌的随机 0/I 期临床试验
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-19-2023
Miguel Quintela-Fandino, Serafín Morales, Alfonso Cortés-Salgado, Luis Manso, Juan V Apala, Manuel Muñoz, Ariadna Gasol Cudos, Joel Salla Fortuny, María Gion, Antonio Lopez-Alonso, Javier Cortés, Juan Guerra, Diego Malón, Eduardo Caleiras, Francisca Mulero, Silvana Mouron